LT-626

LT-626 is a potent PARP inhibitor with an IC50 of 1.60 nM. LT-626 inhibits cellular PAR synthesis with an EC50 of 17.9 nM and shows enhanced cytotoxicity in colorectal cancer cells harboring MRE11 mutations. LT-626 exhibits synergistic effects with Cisplatin (HY-17394), Oxaliplatin (HY-17371), and SN-38 (HY-13704) in colorectal cancer cells. LT-626 can be used for colorectal research[1].

Product Specifications

CAS Number

[1207456-03-8]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

PARP

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Field of Research

Cancer

Smiles

CN1C([C@H]2C=3C4=C(N[C@@H]2C5=CC=C(F)C=C5)C=C(F)C=C4C(=O)NN3)=NC=C1

Molecular Formula

C20H15F2N5O

Molecular Weight

379.37

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]McPherson LA, et al. Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. Cancer Lett. 2014 Feb 28;343 (2) :217-23.